目的：通过观察还原型谷胱甘肽（GSH）治疗对慢性阻塞性肺疾病（COPD）稳定期患者血浆超氧化物歧化酶（SOD）、丙二醛（MDA）、血浆脂质过氧化物（LPO）的变化与肺功能[一秒用力呼气容积占预计值百分比（FEV1%）、一秒用力呼气容积与用力肺活量比值（FEV1/FVC%）]的影响，以评价GSH对COPD的治疗作用。方法选择COPD患者64例，随机分为观察组（GSH联合常规治疗）和对照组（常规治疗），每组各32例。测定并比较两组治疗前和治疗12周后血浆SOD、MDA、LPO及肺功能水平。结果观察组治疗12周后SOD活性高于治疗前（P<0.05），也较对照组明显升高（P<0.05）；而MDA、LPO含量观察组治疗后较治疗前明显降低（P<0.05），也较对照组明显降低（P<0.05）；观察组肺功能明显改善，较对照组肺功能改善差异有统计学意义（P<0.05）。结论 GSH治疗可通过提高机体抗氧化能力，清除氧自由基和脂质过氧化物，对COPD患者有一定辅助治疗的作用，并且能改善肺功能。%ObjectiveTo investigate the clinical effects of glutathione(GSH)therapy for chronic obstructive pulmonary disease(COPD) patients by determine the plasma superoxide dismutase(SOD),malondialdehyde(MDA),plasma lipid peroxides(LPO)and lung function (FEV1%,FEV1/FVC%),by which to evaluate the effect of GSH on COPD.Methods64 patients with COPD were randomly divided into experimental group(GSH combined conventional treatment)and control group(conventional therapy). Measured and compared the plasma SOD,MDA,LPO and lung function levels within the two groups before the treatment and after 12 weeks.ResultsThe activity of SOD in the experimental group after 12 weeks of treatment was higher than that before the treatment(P<0.05); and the MDA,LPO in the experimental group after treatment was significantly lower than before(P<0.05),but also significantly lower than the control group(P<0.05);compared with the control group,the lung function of experimental group improved significantly,and there was significant improvement in lung function(P<0.05). ConclusionApplication of GSH in adjuvant treatment of COPD can achieve significant curative effect,and can improve the lung function of patients.
展开▼
